Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.47 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL29077067 | 1.00 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL29350175 | 0.96 | CA4 (0.50) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL4950260 | 0.96 | LMNA (0.48) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL30390490 | 0.96 | CA4 (0.50) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL3858 | 0.96 | CA4 (0.50) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL4896926 | 0.96 | TSHR (0.44) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL19030905 | 0.93 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL6048227 | 0.93 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL1564 | 0.93 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM | |
| Cadaverine Tartrate SCHEMBL10955358 | 0.93 | CA4 (0.47) | CA4FAHD1LMNATSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5583125-A | SKIN DISORDERS, ANTITUMOR AGENTS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-10 | — | — | US | disclosed |